Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 6/20 | 0.32 |
| ▸ | MAOA | P21397 | 6/20 | 0.32 |
| ▸ | MAOB | P27338 | 6/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281846 | 0.82 | DRD2 (0.33) | BACE1BACE2KDM1AMAOAMAOB | |
| SCHEMBL15757326 | 0.78 | BACE1 (0.37) | BACE1BACE2ALDH1A1RENAPP | |
| SCHEMBL4284969 | 0.76 | TAAR1 (0.35) | — | |
| SCHEMBL4277664 | 0.76 | ALDH1A1 (0.41) | ALDH1A1APP | |
| SCHEMBL2911025 | 0.74 | MAPT (0.40) | ALDH1A1 | |
| SCHEMBL4282740 | 0.74 | — | — | |
| SCHEMBL2912030 | 0.71 | OPRM1 (0.31) | — | |
| SCHEMBL14656129 | 0.70 | BACE1 (0.37) | BACE1BACE2ALDH1A1KDM1AMAOA | |
| SCHEMBL4277498 | 0.70 | MAPT (0.46) | ALDH1A1MAOAMAOBAPP | |
| SCHEMBL884891 | 0.70 | TDO2 (0.36) | ALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | claimed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | claimed |
| JP-2002540204-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1165545-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058305-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-10-05 | — | — | WO | claimed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| CN-115448906-B | 2-anilinopyrimidine derivative and preparation method and application thereof | 深圳大学 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024048697-A1 | COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND | 国立大学法人京都大学 | 2024-03-07 | — | — | WO | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115448906-A | 2-anilinopyrimidine derivative and preparation method and application thereof | 深圳大学 | 2022-12-09 | — | — | CN | disclosed |
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| EP-1725540-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095359-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC | 2005-09-22 | — | — | US | disclosed |
| US-6946478-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-20030134840-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-6518286-B1 | Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma | ASTRAZENECA AB (SE) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009531-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | BACE1 2589/4885BACE2 3491/4885ALDH1A1 2017/4885 |
| US-20030134840-A1 | Novel compounds | RPS4X, RPS4Y1, CYP4B1 | BACE1 1595/4885BACE2 2349/4885ALDH1A1 1521/4885 |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | P2RX3, P2RX2, P2RX1 | BACE1 4402/4885BACE2 4502/4885ALDH1A1 2010/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | BACE1 2589/4885BACE2 3491/4885ALDH1A1 2017/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | BACE1 2589/4885BACE2 3491/4885ALDH1A1 2017/4885 |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | P2RX3, P2RX2, P2RX1 | BACE1 4784/4885BACE2 4826/4885ALDH1A1 2230/4885 |
| US-20200115347-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | BACE1 2589/4885BACE2 3491/4885ALDH1A1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.